Advanced Search

Study Preview



Study Title and Description

Randomized double blind clinical trial on the effect of oral α-cyclodextrin on serum lipids.



Key Questions Addressed
1 Is this an intervention study?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Randomized double blind clinical trial on the effect of oral α-cyclodextrin on serum lipids.
Author Amar MJ., Kaler M., Courville AB., Shamburek R., Sampson M., Remaley AT.
Country Lipoprotein Metabolism Section, Cardio-Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Building 10, Room 8 N-228, 10 Center Drive MSC 1666, Bethesda, MD, USA. ma90x@nih.gov.
Year 2016
Numbers Pubmed ID: 27405337

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Fiber 4.1
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
pubyear 2016
  • Comments Comments (
    0
    ) |
country United States
  • Comments Comments (
    0
    ) |
design Randomized Controlled Trial (Crossover)
  • Comments Comments (
    0
    ) |
blindness Double blind
  • Comments Comments (
    0
    ) |
diet Isocaloric/Maintenance
  • Comments Comments (
    0
    ) |
feedcontrol Food partially provided (partial metabolic study)
  • Comments Comments (
    0
    ) |
sampsize 89
  • Comments Comments (
    0
    ) |
runin No
  • Comments Comments (
    0
    ) |
washout Yes
  • Comments Comments (
    0
    ) |
dosechange No
  • Comments Comments (
    0
    ) |
age_adult 1
  • Comments Comments (
    0
    ) |
age_adol 1
  • Comments Comments (
    0
    ) |
age_child
  • Comments Comments (
    0
    ) |
age_baby
  • Comments Comments (
    0
    ) |
age_infant
  • Comments Comments (
    0
    ) |
age_oth
  • Comments Comments (
    0
    ) |
age_mean 34
  • Comments Comments (
    0
    ) |
age_range 18-75
  • Comments Comments (
    0
    ) |
bmi_mean 25
  • Comments Comments (
    0
    ) |
bmi_range >=18.5
  • Comments Comments (
    0
    ) |
blhealth_healthy 1
  • Comments Comments (
    0
    ) |
blhealth_hyperlip
  • Comments Comments (
    0
    ) |
blhealth_diab
  • Comments Comments (
    0
    ) |
blhealth_hyperten
  • Comments Comments (
    0
    ) |
blhealth_digest
  • Comments Comments (
    0
    ) |
blhealth_met
  • Comments Comments (
    0
    ) |
blhealth_oth
  • Comments Comments (
    0
    ) |
blhealth_othspec
  • Comments Comments (
    0
    ) |
gender ~45
  • Comments Comments (
    0
    ) |
ftype1 Alphacyclodextrin
  • Comments Comments (
    0
    ) |
descrip1_1
  • Comments Comments (
    0
    ) |
descrip1_2
  • Comments Comments (
    0
    ) |
dose1_1 6
  • Comments Comments (
    0
    ) |
dose1_2
  • Comments Comments (
    0
    ) |
duration1 12-14 weeks
  • Comments Comments (
    0
    ) |
admin1 Tablet
  • Comments Comments (
    0
    ) |
ftype2
  • Comments Comments (
    0
    ) |
descrip2_1
  • Comments Comments (
    0
    ) |
descrip2_2
  • Comments Comments (
    0
    ) |
dose2_1
  • Comments Comments (
    0
    ) |
dose2_2
  • Comments Comments (
    0
    ) |
duration2
  • Comments Comments (
    0
    ) |
admin2
  • Comments Comments (
    0
    ) |
ftype3
  • Comments Comments (
    0
    ) |
descrip3_1
  • Comments Comments (
    0
    ) |
descrip3_2
  • Comments Comments (
    0
    ) |
dose3_1
  • Comments Comments (
    0
    ) |
dose3_2
  • Comments Comments (
    0
    ) |
duration3
  • Comments Comments (
    0
    ) |
admin3
  • Comments Comments (
    0
    ) |
ftype4
  • Comments Comments (
    0
    ) |
descrip4_1
  • Comments Comments (
    0
    ) |
descrip4_2
  • Comments Comments (
    0
    ) |
dose4_1
  • Comments Comments (
    0
    ) |
dose4_2
  • Comments Comments (
    0
    ) |
duration4
  • Comments Comments (
    0
    ) |
admin4
  • Comments Comments (
    0
    ) |
comparator1 placebo
  • Comments Comments (
    0
    ) |
cdose1 0
  • Comments Comments (
    0
    ) |
cduration1 12-14 weeks
  • Comments Comments (
    0
    ) |
cadmin1 Tablet
  • Comments Comments (
    0
    ) |
comparator2
  • Comments Comments (
    0
    ) |
cdose2
  • Comments Comments (
    0
    ) |
cduration2
  • Comments Comments (
    0
    ) |
cadmin2
  • Comments Comments (
    0
    ) |
comparator3
  • Comments Comments (
    0
    ) |
cdose3
  • Comments Comments (
    0
    ) |
cduration3
  • Comments Comments (
    0
    ) |
cadmin3
  • Comments Comments (
    0
    ) |
comparator4
  • Comments Comments (
    0
    ) |
cdose4
  • Comments Comments (
    0
    ) |
cduration4
  • Comments Comments (
    0
    ) |
cadmin4
  • Comments Comments (
    0
    ) |


Baseline Characteristics
No baseline characteristics have been defined for this extraction form.



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Comments

Quality Dimensions
No quality dimensions were specified.

Quality Rating
No quality rating data was found.